title: Immunotherapy in new pre-clinical models of HPV-associated oral cancers.
abstract: Cervical, anal, penile and a sub-set of head and neck (HN) tumors are critical health problems caused by high risk Human Papilloma Viruses (HPVs), like HPV type 16. No specific/effective pharmacological treatments exist. A valid preventive vaccination as well as the immunotherapy of persistent infections, pre-cancerous lesions or early-stage cancers could drive the HPV disease burden down. These treatments might be featured through low-cost platforms like those based on DNA and plant biotechnologies to produce tailored and enhanced formulations taking profit from the use of plants as bio-factories and as a source of immune-stimulators. Finally, and regardless of the formulation type, pre-clinical tests and models are crucial to foresee efficacy of immunotherapy before clinical trials.   In this study, we created an orthotopic mouse model for HPV-related oral tumors, a subset of HN tumors for which no models have been generated before. The model was obtained by inducing the stable expression of the HPV16 E7 protein into the mouse oral squamous cell carcinoma (OSCC) AT-84 (AT-84 E7). The AT-84 E7 cells were injected into the mouth pavement of C3H mice via an extra-oral route to obtain orthotopic tumors. The model turned out to mimic the natural history of the human HPV oral cancer. From AT-84 E7, through engineering to express luciferase, the bioluminescent AT-84 E7-Luc cells were obtained for a fast and easy monitoring by imaging. The AT-84 E7 and the AT-84 E7-Luc tumors were used to test the efficacy of E7-based therapeutic vaccines that we had previously generated and that had been already proven to be active in mice against non-orthotopic E7-expressing tumors (TC-1 cells). In particular, we used genetic and plant-derived formulations based on attenuated HPV16 E7 variants either fused to plant virus genes with immunological activity or produced by tobacco plants. Mice were monitored by imaging allowing to test the size reduction of the mouth implanted experimental tumors in function of the different regimens used. The proposed tumor model is easy to handle and to reproduce and it is efficacious in monitoring immunotherapy. Furthermore, it is expected to be more predictive of clinical outcome of therapeutic vaccines than non-orthotopic models that are currently used. Finally, imaging offers unique opportunities to predict formulation efficacy through measuring tumor growth in vivo.
authors.affiliation: Laboratory of Virology; Regina Elena National Cancer Institute; Rome, Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Paolini
authors.forename: Silvia
authors.initials: S
authors.lastname: Massa
authors.forename: Isabella
authors.initials: I
authors.lastname: Manni
authors.forename: Rosella
authors.initials: R
authors.lastname: Franconi
authors.forename: Aldo
authors.initials: A
authors.lastname: Venuti
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D017930:Genes, Reporter; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008156:Luciferases / Q000032:analysis / Q000235:genetics; D008809:Mice, Inbred C3H; D009062:Mouth Neoplasms / Q000628:therapy*; D030361:Papillomavirus Infections / Q000150:complications* / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines; D008156:Luciferases
keywords: DNA vaccines; E7 protein; head and neck tumors; human papilloma virus; imaging; orthotopic models; plant-derived vaccines; tumor immunity